Back to all peptides

    Complete this with

    The Desire Peptide Protocol

    Evidence before a stack. Approval, benefit and risk depend on the specific compound and indication. Nervous-system coaching does not replace clinical assessment. Explore the 7-Day Reset and your matched The Desire Peptide Protocol for optional wellbeing support, not permission to self-prescribe.

    Anchor 15 · Desire Peptide ProtocolClinically established

    PT-141 (Bremelanotide)

    Melanocortin (MC3R / MC4R) receptor agonist

    Restore the signal, do not force the response.

    US approval is narrow: acquired, generalized HSDD in premenopausal women, not sexual performance enhancement, men, or postmenopausal women. The label excludes low desire attributable to another condition, medication or relationship problems. US approval does not establish access in Portugal.

    42 currently viewing

    Evidence classification

    Clinically established. FDA-approved or equivalent regulatory authorization for at least one indication.

    Evidence reviewed · 2026-10-21

    What the evidence actually supports

    Bremelanotide / Vyleesi

    US approval is narrow: acquired, generalized HSDD in premenopausal women, not sexual performance enhancement, men, or postmenopausal women. The label excludes low desire attributable to another condition, medication or relationship problems. US approval does not establish access in Portugal.

    Contraindicated with uncontrolled hypertension or known cardiovascular disease, not just above an invented blood-pressure cutoff. Nausea, temporary blood-pressure increases and potentially persistent pigmentation matter. Medication decisions and local availability belong with the prescriber.

    Before you layer this peptide

    Foundation checklist

    These are discussion points, not eligibility rules. No wearable score, supplement stack or thirty-day routine establishes that PT-141 (Bremelanotide) is appropriate.

    • Completed the 7-Day Reset — optional support for observing sleep, stress and recovery.
    • Review sleep and recovery. A diary can help; a wearable is optional and cannot diagnose a nervous-system state.
    • Investigate persistent symptoms. Fatigue, pain or cognitive changes may have medical causes. HRV alone cannot identify them.
    • Running the 4 pillars of The Desire Peptide Protocol — supplement stack, timing dashboard, device pairings, and macro rules. The full protocol is available inside the Anchor.
    • Nutrition matched to your health and treatment. Fasting and supplements are not universal requirements; review them with your clinician.
    • Clinical review when indicated. Your clinician decides which tests, if any, are appropriate; a blanket panel is not a safety certificate.
    • Qualified prescriber on board. PT-141 (Bremelanotide) is sourced, dosed, and monitored under medical supervision — not from a research-chemical vendor.
    Open the The Desire Peptide Protocol

    Mechanism of action

    US approval is narrow: acquired, generalized HSDD in premenopausal women, not sexual performance enhancement, men, or postmenopausal women. The label excludes low desire attributable to another condition, medication or relationship problems. US approval does not establish access in Portugal.

    Who this is for

    • ●Readers comparing actual human evidence with marketing claims.
    • ●Adults discussing an appropriate, locally authorized treatment or clinical trial with their clinician.

    Who this is not for

    • ○Self-prescribing, sourcing research vials or substituting this guide for clinical assessment.
    • ○Pregnancy, breastfeeding or complex medical conditions without individualized medical review.

    Treatment and protocol boundaries

    No self-injection or experimental dosing instructions. Approved medicines follow their own label and prescriber plan.

    Clinical boundaryContraindicated with uncontrolled hypertension or known cardiovascular disease, not just above an invented blood-pressure cutoff. Nausea, temporary blood-pressure increases and potentially persistent pigmentation matter. Medication decisions and local availability belong with the prescriber.

    Sourcing & quality

    Where this comes from matters more than the molecule

    Use only lawfully supplied medicines for an appropriate indication, or a formally approved clinical trial. A research-use label or purity assay does not make a product suitable for human treatment. Ask a clinician or pharmacist to verify local authorization and availability; US approval alone does not establish access in Portugal.

    Support around treatment

    Sleep, food, movement and symptom tracking are support pillars, not proven peptide enhancers. Supplements and devices can have their own risks; more is not automatically better.

    Sleep and recovery

    Track how you feel and function; sleep is support, not evidence that a peptide works.

    Nutrition and movement

    Individualize food and activity with your care team. Supplement combinations are not automatically necessary or safe.

    Journal and clinician review

    Record symptoms and treatment changes without assuming every change was caused by the molecule.

    Known risks & side effects

    • ▲Nausea — the most common side effect, especially on first use; often improves with subsequent doses.
    • ▲Flushing, headache, and dizziness in the hours after dosing.
    • ▲Transient blood pressure increase (≈6 mmHg systolic) — caution in hypertension or cardiovascular disease.
    • ▲Focal hyperpigmentation with frequent or repeated use, especially in darker skin tones.
    • ▲Injection site reactions.
    • ▲Not a long-term daily protocol — chasing the dose past the monthly cap escalates risk without escalating benefit.

    Common questions

    What does the current evidence support?

    US approval is narrow: acquired, generalized HSDD in premenopausal women, not sexual performance enhancement, men, or postmenopausal women. The label excludes low desire attributable to another condition, medication or relationship problems. US approval does not establish access in Portugal.

    Does an Anchor replace clinical care?

    No. An Anchor offers optional coaching support. It is not a prescribing service, a safety certificate or a medical requirement before an approved treatment.

    Where are the dosing instructions?

    Contraindicated with uncontrolled hypertension or known cardiovascular disease, not just above an invented blood-pressure cutoff. Nausea, temporary blood-pressure increases and potentially persistent pigmentation matter. Medication decisions and local availability belong with the prescriber.

    The matched Anchor

    Complete this peptide with The Desire Peptide Protocol

    Optional coaching for the everyday habits around care. This Anchor does not establish peptide efficacy, authorize prescribing or replace medical treatment.

    "Restore the signal, do not force the response. Erotic access, not performance theatre."

    Targets

    Low Desire & Erotic Signal Loss

    Category

    Desire (Peptide)

    Fasting window

    Modest only — desire rarely thrives in a depleted body

    Inside the full Anchor

    • ·4 supplement pillars with sourced products
    • ·Hour-by-hour timing dashboard
    • ·Device pairings & macro rules
    • ·Current protocol in-app — lifetime access
    Unlock the full The Desire Peptide Protocol

    Build the floor first

    Interventions without an Anchor is biohacking. With one, it's architecture.

    The Desire Peptide Protocol sets the supplement, device, and fasting baseline this peptide is designed to layer on top of.

    See the Desire Peptide Protocol Discover what fits you

    Medical disclaimer. Kokorology is an educational publication. The information on this page is not medical advice and does not establish a doctor-patient relationship. Peptides are pharmacologically active compounds. Several peptides referenced across this site are not approved by the FDA, EMA, or equivalent regulators for general wellness use; some are research compounds or approved only for narrow indications (e.g. tesamorelin for HIV-associated lipodystrophy). The FDA has issued warnings about unapproved compounded GLP-1 products. Never start, change, or stop a peptide protocol without a qualified prescriber. If you are pregnant, nursing, taking prescription medication, or have a chronic condition, do not begin any protocol described here without medical supervision.